Altaner, SemsiYoruk, YenerTokatli, FusunKocak, ZaferTosun, BirsenGuresci, ServetKutlu, Kemal2024-06-122024-06-1220060300-89162038-2529https://doi.org/10.1177/030089160609200411https://hdl.handle.net/20.500.14551/18089Aims and background: Thyroid transcription factor (TTF-1) is a tissue-specific transcription factor expressed in the epithelial cells of thyroid and lung. The aim of this study was to evaluate the relationship between the expression of TTF-1 and clinicopathological parameters in pulmonary adenocarcinoma and adenosquamous carcinoma. Methods: Resection material of pneumonectomies and lobectomles of 39 patients was retrospectively examined. Twenty-eight patients were diagnosed with adenocarcinoma and 11 with adenosquamous carcinoma. Tumors were classified into 3 groups: a strongly positive group (++) with double dagger 50% tumor cells positive for TTF-1; a weakly positive group (+) with 1-49% positive tumor cells; and a negative group (-) with less than 1% or no positive tumor cells. Analysis was performed with Kaplan-Meier estimates and log-rank tests. Results: Staining for TTF-1 was negative in 10 cases. There was focal staining in 9 cases, while there was diffuse staining in 20 (51%) cases out of 39, and 15 (75%) of these were adenocarcinomas. There was a statistically significant association between TTF-1 and lymph node metastases (P = 0.029). No relationship was found between TTF-1 positivity and disease-free and overall survival. Conclusions: TTF-1 expression may be a predictor of lymph node metastases. Additional work in a larger group of patients is needed to better assess the utility of this marker.en10.1177/030089160609200411info:eu-repo/semantics/closedAccessAdenocarcinomaAdenosquamous CarcinomaLungPrognosisTTF-1Transcription Factor-IEnhancer-Binding ProteinCell CarcinomasGeneExpressionArticle924323326N/AWOS:0002409203000112-s2.0-3374956632117036524Q3